Heteroaromatic bicyclic derivatives useful as anticancer agents

{
  "publication_number": "US2003055049A1",
  "country": "US",
  "kind": "A1",
  "title": "Heteroaromatic bicyclic derivatives useful as anticancer agents",
  "abstract": "The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R 1, R 3 and R 4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.",
  "claims": [
    "1. A compound of the formula 1 or a pharmaceutically acceptable salt or solvate thereof, wherein: X is N or CH; A represents a fused 5, 6 or 7-membered ring optionally containing 1 to 4 heteroatoms which may be the same or different and which are selected from - N(R 1) -, O, and S(O) j, wherein j is an integer from 0 to 2, the fused ring containing a total of 1, 2 or 3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused wherein the R 1 group attached to the nitrogen is absent if a double bond includes the foregoing optional nitrogen moiety - N(R 1) -, with the proviso that the fused ring does not form part of a purine and that the fused ring does not contain two adjacent O or S(O) j atoms, and wherein the carbon atoms of the A moiety are optionally substituted by 1 to 3 R 5 groups; each R 1 and R 2 is independently H or C 1 -C 6 alkyl; R 3 is - (CR 1 R 2) m - R 8 wherein m is 0 or 1; or R 1 and R 3 are taken together to form a group of the formula wherein said group is optionally substituted with 1 to 3 R 5 groups; R 4 is - (CR 1 R 2) t (C 6 -C 10 aryl) or - (CR 1 R 2) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, wherein said R 4 groups are substituted with 1 to 3 groups independently selected from - (CR 1 R 2) q NR 1 R 9, - (CR 1 R 2) q NR 9 (C 1 -C 6 alkanoyl), - (CR 1 R 2) q O(CR 1 R 2) r R 9, and - (CR 1 R 2) q R 9 wherein q and r are each independently an integer from 0 to 5, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R 10 groups; each R 5 is independently selected from halo, hydroxy, - NR 1 R 2, C 1 -C 6 alkyl, trifluoromethyl, C 1 -C 6 alkoxy, and trifluoromethoxy; each R 6 and R 7 is independently selected from H, C 1 -C 6 alkyl, - (CR 1 R 2) t (C 6 -C 10 aryl), and - (CR 1 R 2) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (═O) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R 6 and R 7 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, - NR 1 R 2, trifluoromethyl, trifluoromethoxy, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, hydroxy, and C 1 -C 6 alkoxy; each R 8 is independently selected from - (CR 1 R 2) t (C 6 -C 10 aryl) and - (CR 1 R 2) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (═O) moiety, and each of the foregoing R 8 groups is optionally substituted with 1 to 5 R 10 groups; R 9 is a fused or bridged bicyclic ring or a spirocyclic ring, wherein said ring contains from 5 to 12 carbon atoms in which up to 2 carbon atoms are optionally replaced with a hetero moiety selected from O, S(O) j wherein j is an integer from 0 to 2, and - NR 11 -, provided that two O atoms, two S(O) j moieties, an O atom and a S(O) j moiety, an N atom and an S atom, or an N atom and an O atom are not attached directly to each other, and wherein said ring is saturated or partially unsaturated with up to two carbon-carbon double bonds, and the carbon atoms of said ring are optionally substituted with 1 to 4 R 10 groups; or where R 9 is as - NR 1 R 9 then R 9 optionally can be taken together with R 1 and the nitrogen to which R 1 and R 9 are attached to form a fused or bridged bicyclic ring or a spirocyclic ring, wherein said ring is saturated and contains from 5 to 12 carbon atoms in which up to 2 carbon atoms are optionally replaced with a hetero moiety selected from O, S(O) j wherein j is an integer from 0 to 2, and - NR 1 -, provided that two O atoms, two S(O) j moieties, or an O atom and a S(O) j moiety are not attached directly to each other, and wherein the carbon atoms of said rings are optionally substituted with 1 to 4 R 10 groups; each R 10 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C 1 -C 6 alkoxy, C 1 -C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, - C(O)R 5, - C(O)OR 6, - OC(O)R 6, - NR 6 C(O)R 7, - C(O)NR 6 R 7, - NR 6 R 7, - NR 6 OR 7, - SO 2 NR 6 R 7, - S(O) j (C 1 -C 6 alkyl) wherein j is an integer from 0 to 2, - (CR 1 R 2) q C(O)(CR 1 R 2) t (C 6 -C 10 aryl), - (CR 1 R 2) q C(O)(CR 1 R 2) t (4-10 membered heterocyclic), - (CR 1 R 2) t O(CR 1 R 2) q (C 6 -C 10 aryl), - (CR 1 R 2) t O(CR 1 R 2) q (4-10 membered heterocyclic), - (CR 1 R 2) t O(CR 1 R 2) q (C 6 -C 10 aryl), - (CR 1 R 2) t O(CR 1 R 2) q (4-10 membered heterocyclic), - (CR 1 R 2) q SO 2 (CR 1 R 2) t (C 6 -C 10 aryl, and - (CR 1 R 2) q SO 2 (CR 1 R 2) t (4-10 membered heterocyclic), wherein q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R 10 groups are optionally substituted with an oxo (═O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R 10 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, - OR 6, - C(O)R 6, - C(O)OR 6, - OC(O)R 6, - NR 6 C(O)R 7, - C(O)NR 6 R 7, - NR 6 R 7, - NR 6 OR 7, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, - (CR 1 R 2) t (C 6 -C 10 aryl), and - (CR 1 R 2),(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; R 11 is H, C 1 -C 6 alkyl, - C(O)R 6 or - SO 2 R 6; and wherein any of the above-mentioned substituents comprising a CH 3 (methyl), CH 2 (methylene), or CH (methine) group which is not attached to a halogeno, SO or SO 2 group or to a N, O or S atom optionally bears on said group a substituent selected from hydroxy, halo, C 1 -C 4 alkyl, C 1 -C 4 alkoxy and - NR 1 R 2. 2. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from wherein the above A moieties bear an R 4 group as a substituent and optionally bear 1 to 3 R 5 groups as substituents. 3. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from wherein the above A moieties bear an R 4 group as a substituent and optionally bear 1 to 3 R 5 groups as substituents. 4. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from wherein the above A moieties bear an R 4 group as a substituent and optionally bear 1 to 3 R 5 groups as substituents. 5. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from wherein the above A moieties bear an R 4 group as a substituent and optionally bear 1 to 3 R 5 groups as substituents. 6. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is wherein the above A moieties bear an R 4 group as a substituent and optionally bear 1 to 3 R 5 groups as substituents. 7. A compound according to claim 5 wherein R 4 is - (CR 1 R 2) t (C 6 -C 10 aryl) or - (CR 1 R 2) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, wherein said R 4 groups are substituted with 1 to 3 groups independently selected from - (CR 1 R 2) q NR 1 R 9, - (CR 1 R 2) q NR 9 (C 1 -C 6 alkanoyl), - (CR 1 R 2) q O(CR 1 R 2) r R 9, and - (CR 1 R 2) q R 9 wherein q and r are each independently an integer from 0 to 3, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R 10 groups. 8. A compound according to claim 6 wherein R 4 is - (CR 1 R 2) t (C 6 -C 1 aryl) or - (CR 1 R 2) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, wherein said R 4 groups are substituted with 1 to 3 groups independently selected from - (CR 1 R 2) q NR 1 R 9, - (CR 1 R 2) q NR 9 (C 1 -C 6 alkanoyl), - (CR 1 R 2) q O(CR 1 R 2) r R 9, and - (CR 1 R 2) q R 9 wherein q and r are each independently an integer from 0 to 3, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R 10 groups. 9. A compound according to claim 5 wherein R 3 is - (CR 1 R 2) m - R 8 wherein m is 0 or 1 and R 8 is selected from - (CR 1 R 2) t (phenyl), - (CR 1 R 2) t (pyridyl), - (CR 1 R 2) t (pyrimidinyl), - (CR 1 R 2) t (indolyl), - (CR 1 R 2) t (indazolyl) and - (CR 1 R 2) t (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R 8 groups is optionally substituted with 1 to 5 R 10 groups. 10. A compound according to claim 6 wherein R 3 is - (CR 1 R 2) m - R 8 wherein m is 0 or 1 and R 8 is selected from - (CR 1 R 2) t (phenyl), - (CR 1 R 2) t (pyridyl), - (CR 1 R 2) t (pyrimidinyl), - (CR 1 R 2) t (indolyl), - (CR 1 R 2) t (indazolyl) and - (CR 1 R 2) t (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R 8 groups is optionally substituted with 1 to 5 R 10 groups. 11. A compound according to claim 7 wherein R 3 is - (CR 1 R 2) m - R 8 wherein m is 0 or 1 and R 8 is selected from - (CR 1 R 2) t (phenyl), - (CR 1 R 2) t (pyridyl), - (CR 1 R 2) t (pyrimidinyl), - (CR 1 R 2) t (indolyl), - (CR 1 R 2) t (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R 8 groups is optionally substituted with 1 to 5 R 10 groups. 12. A compound according to claim 8 wherein R 3 is - (CR 1 R 2) m - R 8 wherein m is 0 or 1 and R 8 is selected from - (CR 1 R 2) t (phenyl), - (CR 1 R 2) t (pyridyl), - (CR 1 R 2) t (pyrimidinyl), - (CR 1 R 2) t (indolyl), - (CR 1 R 2) t (indazolyl) and - (CR 1 R 2) t (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R 8 groups is optionally substituted with 1 to 5 R 10 groups. 13. A compound according to claim 1 selected from the group consisting of: {6-[4-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(4-phenoxy-phenyl)-amine; (3-{4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (3-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (3-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine; (6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-benzyl-phenyl)-amine; 6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(1-benzenesulfonyl-1H-indol-5-yl)-amine; 6-{4-[(3-Aza-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine; 3-{4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzylamino}-8-methyl-8-aza-bicyclo[3.2.1]octan-6-ol; (4-Benzyl-phenyl)-{6-[4-(6-methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-amine {6-[4-(6-Methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-}-(4-phenoxy-phenyl)-amine; (3-{4-[4-(4-[1,2,3]Thiadiazol-5-yl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (3-{4-[4-(4-Cyclohexyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (3-{4-[4-(4-p-Tolyloxy-phenylamino)-quinazolin)-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (3-{4-[4-(Biphenyl-4-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (3-{4-[4-(4-Ethyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; 4-{6-[4-(6-Hydroxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-ylamino)-N-phenyl-benzamide; [3-(4-{4-[1-(Propane-2-sulfonyl)-1H-indol-5-ylamino]-quinazolin-6-yl}-benzyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-methanol; (3-{4-[4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (1-Benzenesulfonyl-1H-indol-5-yl)-(6-{4-[(3-oxa-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-amine; 8-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}aza-bicyclo[3.2.1]octan-3-ol; 8-(4-{4-[1-(Propane-2-sulfonyl)-1H-indol-5-ylamino]-quinazolin-6-yl}-benzyl)-8-aza-bicyclo[3.2.1]octan-3-ol; 8-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol; 8-{4-[4-(1-Benzyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol; (3-{4-[4-(6-Phenoxy-pyridin-3-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; (3-{5-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol; {3-[4-(4-Phenoxy-phenylamino)-quinazolin-6ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-yl}methanol; (5-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol; (5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol; (6-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-6-aza-spiro[2.5]oct-1-yl)-methanol; (6-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-6-azaspiro[2.5]oct-1-yl)-methanol; (5-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.4]hept-1-yl)-methanol; (5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.4]hept-1-yl)-methanol; (5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol; and the pharmaceutically acceptable salts and solvates of the foregoing compounds. 14. A method for the treatment of abnormal cell growth in a mammal comprising administering to said mammal an amount of a compound of claim 1 that is effective in treating abnormal cell growth. 15. A method according to claim 14 wherein said abnormal cell growth is cancer. 16. A method according to claim 15 wherein said cancer is selected from lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. 17. A method according to claim 14 wherein said abnormal cell growth is a benign proliferative disease. 18. A method according to claim 17 wherein said abnormal cell growth is selected from psoriasis, benign prostatic hypertrophy and restinosis. 19. A method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of claim 1 that is effective in treating abnormal cell growth in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens. 20. A pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of claim 1 that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier. 21. A method of preparing a compound of claim 1 which comprises either (a) reacting a compound of the formula 5 with a compound of the formula 6 wherein Z is a leaving group and A, X, R 1, R 3, and R 4 are as defined in claim 1, or (b) reacting a compound of the formula 2 with a compound of the formula 6 wherein X, A, R 1, and R 3 are as defined in claim 1 and Z 1 is an activating group, to provide an intermediate of the formula 7 wherein Z 1, X, A, R 1, and R 3 are as defined in claim 1, and treating the compound of formula 7 with a coupling partner of the formula X 1 - (CR 1 R 2) t (C 6 -C 10 aryl) or X 1 - (CR 1 R 2) t (4-10 membered heterocyclic), wherein t, R 1 and R 2 are as defined in claim 1 as provided in the definition of R 4, the aryl and heterocyclic groups of the foregoing groups are substituted with a group that includes an aldehyde or acid moiety, and X 1 is - B(OH) 2 or - Sn(C 1 -C 5 alkyl) 3, to provide a compound of formula 8 wherein X, A, R 1, and R 3 are as defined above, and Z 2 is - (CR 1 R 2) t (C 6 -C 10 aryl) or - (CR 1 R 2) t (4-10 membered heterocyclic), wherein t, R 1 and R 2 are as defined in claim 1, and the aryl and heterocyclic groups of the foregoing Z 2 groups are substituted with a group that includes an aldehyde or acid moiety, and modifying said aldehyde or acid moiety to introduce a group selected from - (CR 1 R 2) q NR 1 R 9, - (CR 1 R 2) q NR 9 (C 1 -C 6 alkanoyl), - (CR 1 R 2) q OR 9, and - (CR 1 R 2) q R 9, wherein R 1, R 2, R 9, and q are as defined in the definition of R 4 in claim 1."
  ],
  "description_excerpt": "This invention relates to novel bicyclic derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds. [0001]\n\nIt is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e., a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins that are aberrant tyrosine kinases capable of causing cell transformation. Alternatively, the overexpression of a normal proto-oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype. [0002]\n\nReceptor tyrosine kinases are enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation. Other receptor tyrosine kinases include c-erbB-2, c-met, tie-2, PDGFr, FGFr, VEGF and TGF-β. It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer.",
  "cpc": [
    "C07D 401/10",
    "A61K 45/06",
    "A61P 35/00",
    "A61P 35/04",
    "C07D 239/94",
    "C07D 403/10",
    "C07D 405/12",
    "C07D 451/02",
    "C07D 453/02"
  ],
  "ipc": [
    "A61K 31/437",
    "A61K 31/4375",
    "A61K 31/439",
    "A61K 31/46",
    "A61K 31/517",
    "A61K 31/519",
    "A61K 45/06",
    "A61P 35/00",
    "C07D 239/94",
    "C07D 401/10",
    "C07D 403/10",
    "C07D 403/14",
    "C07D 405/12",
    "C07D 417/14",
    "C07D 451/02",
    "C07D 451/04",
    "C07D 451/06",
    "C07D 453/02",
    "C07D 471/04"
  ],
  "assignees": [
    "Pfizer Inc"
  ],
  "inventors": [
    "John Kath",
    "Norma Tom",
    "Eric Cox",
    "Samit Bhattacharya"
  ],
  "filing_date": "2002-08-22",
  "publication_date": "2003-03-20",
  "priority_date": "1999-01-27",
  "application_number": "US-22625502-A",
  "family_id": "22372363",
  "cited_by_count": 69
}